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Abstract: The absorption of non‐steroidal anti‐inflammatory drugs (NSAIDs) through the nasal 9 
epithelium offers an innovative opportunity in the field of pain therapy. Thanks to the bonding of 10 
chitosan to the nasal mucosa and its permeability‐enhancing effect, it is an excellent choice to for‐ 11 
mulate microspheres for the increase of drug bioavailability. The aim of our work includes the 12 
preparation of spray‐dried cross‐linked and non‐cross‐linked chitosan‐based drug delivery sys‐ 13 
tems for intranasal application, the optimization of spray‐drying process parameters (inlet air 14 
temperature, pump rate) and the composition of samples. Cross‐linked products were prepared 15 
by using different amounts of sodium tripolyphosphate. On top of these, the micrometric proper‐ 16 
ties, the structural characteristics, the in vitro drug release and the in vitro permeability of the 17 
products were studied. Spray‐drying resulted in micronized chitosan particles (2‐4 μm) regardless 18 
of the process parameters. The meloxicam (MEL)‐containing microspheres showed nearly spheri‐ 19 
cal habit while MEL was present in a molecularly dispersed state. The highest dissolved (>90%) 20 
and permeated (~45 ug/cm2) MEL amount was detected from the non‐cross‐linked sample. Our 21 
results indicate that spray‐dried MEL‐containing chitosan microparticles may be recommended 22 
for the development of a novel drug delivery system to decrease acute pain or enhance analgesia 23 
by intranasal application. 24 
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 26 
1. Introduction 27 
Nasal drug delivery provides an opportunity not merely to treat local pathological 28 
conditions (e.g. allergic rhinitis, nasal congestion) but also to deliver active pharmaceu‐ 29 
tical ingredients (APIs) to the systemic circulation or directly through the blood‐brain 30 
barrier to the central nervous system [1]. The nose respiratory region is crucial from the 31 
aspect of systemic drug absorption. Drugs administered intranasally bypass the 32 
first‐pass hepatic metabolism, thus side‐effects are avoided and the large surface and the 33 
high vascularization of the mucosa causes the rapid onset of action [2,3]. Since it is an 34 
easily accessible, non‐invasive and painless option for systemic therapies, it is well ac‐ 35 
cepted by patients [4]. However, there are some limitations that need to be taken into 36 
account. Firstly, mucosa sensitivity can not be neglected, thus, drugs and excipients 37 
intended for intranasal delivery must not be irritant and definitely not toxic [5]. The 38 
mucociliary clearance is a key determinant concerning the APIs residence time. The 39 
mucus layer renews in every 15‐20 minutes (min.), so to prolong the APIsʼ contact time 40 
the use of mucoadhesive polymers can be considered. The low permeability of the mu‐ 41 
cosa raises another problem that needs to be solved [6–8]. 42 
Nasal sprays, drops, gels and ointments are extremely popular and widely used. 43 
Unfortunately, only few nasal powders are accessible on the market, however, they have 44 
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highly beneficial properties over the aforementioned formulations. Since nasal powders 45 
do not contain moisture and their physical stability is better concerning liquid and 46 
semi‐solid formulations, therefore they can be prepared without using preservatives 47 
[9,10]. Moreover, they are eliminated slowly from the nasal cavity, because the better 48 
adhesion allows a longer time period for the API absorption [11]. Particle size, mor‐ 49 
phology or rheological features must be taken into consideration during the nasal pow‐ 50 
der formulation [12,13]. 51 
Chitosan is a semi‐synthetic polymer which is obtained by chitin deacetylation and 52 
mostly it is found in crustaceans or in mushroom cell walls [14]. It plays a key role in the 53 
biomedical field due to its advantegous properties. Chitosan and its derivatives as mi‐ 54 
cro‐ or nanoparticles can be used for the targeted or controlled delivery of antibiotics, 55 
antitumor drugs, proteins or vaccines. They are highly suitable for tissue engineering 56 
and wound healing based on their stimulating effect on cell proliferation and tissue re‐ 57 
generation. In terms of nasal administration, chitosan’s biocompatibility – which is due 58 
to the non‐toxicity of its degradation products to the human body – and mucoadhesive 59 
characteristics are preferred. Due to the cationic nature of chitosan, an ionic bond can be 60 
formed by the interaction between the negatively charged substructures of the mucus 61 
layer and chitosan, enabling mucoadhesion [15,16]. The positive charge interacts with 62 
tight junction‐ associated proteins as well causing the distance growth between epithe‐ 63 
lial cells and enhancing the permeation property of chitosan [17]. Chitosan‐based drug 64 
delivery systems are widely used for achieving controlled drug release. It has been re‐ 65 
ported that by using cross‐linking agents an increased stability could be accomplished 66 
[18]. Glutaraldehyde and formaldehyde were used mainly as cross‐linkers but for their 67 
toxic quality, sodium tripolyphosphate (TPP) may be a more conspicuous alternative 68 
[19]. It possesses a negative charge, so ionic bond is developed between TPP and chito‐ 69 
san [20,21]. 70 
Non‐steroidal anti‐inflammatory drugs (NSAIDs) are essential in relieving acute 71 
pain or enhancing analgesia as adjuvants to opioids [22,23]. The intranasal application of 72 
NSAIDs may offer an opportunity to attain a rapid analgesic effect by their absorption 73 
through the nasal mucosa to the systemic circulation [24]. During the formulation of 74 
NSAIDs, it is inevitable to solve their solubility problems, which can result in dose re‐ 75 
duction that  leads to decreased side effects together with their bioavailability im‐ 76 
provement [25]. Several technological methods are available for modifying the phys‐ 77 
ico‐chemical properties and increasing the dissolution rate of NSAIDs [26–28]. 78 
Spray‐drying is a one‐step production method which can be applied to change the dis‐ 79 
solution properties of a drug and provides an opportunity to prepare microspheres that 80 
match nasal requirements. This technique allows the control of particle properties such 81 
as their shape and size in a rapid and reproducible way [29,30]. It looks promising to 82 
create nasal formulations by spray‐drying for pain relief with adequate dissolution 83 
properties, however, there has not been any available literatures on this topic so far. 84 
In our work, meloxicam (MEL) was chosen as a NSAID. It is used in joint disease 85 
therapy and serves as a favorable option because of its side‐effect profile. A 86 
MEL‐containing nasal formulation may provide an opportunity to ease the pain alone or 87 
to potentiate the effects of opioids. In our previous research works MEL‐ and meloxicam 88 
potassium monohydrate‐containing spray and gel forms were prepared and investi‐ 89 
gated. The goal of this study was to design MEL‐containing mucoadhesive intranasal 90 
microparticles to increase the residence time and bioavailability of drugs by enhancing 91 
their dissolution and permeation. Chitosan microspheres were produced by 92 
spray‐drying process setting the parameters in order to acquire an energy‐saving and a 93 
quick preparation method. The effect of a lower inlet air temperature (90 °C) – 94 
lesser‐known in the literature – was compared with higher air temperatures. Further‐ 95 
more, we optimized the composition of the formulation intended for nasal application 96 
by preparing MEL‐incorporated chitosan‐based microparticles and adding different 97 
amounts of TPP as a cross‐linking agent. Particle size, morphological and rheological 98 
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properties of the products ensured nasal deposition. The physico‐chemical properties, in 99 
vitro dissolution and diffusion were determined and evaluated. 100 
2. Materials and Methods 101 
2.1. Materials 102 
MEL was from EGIS Ltd. (Budapest, Hungary). Low molecular weight chitosan 103 
(Mw = 3800‐20,000 Da) was obtained from Sigma Aldrich (Sigma Aldrich Co. LLC, St. 104 
Louis, MO, USA), TPP was purchased from Alfa Aeasar Co. (Alfa Aeasar GmbH & Co. 105 
KG, Karlsruhe, Germany). Dimethyl sulfoxide was from VWR Chemicals BDH Prolabo 106 
and Acetic acid was from Molar Chemicals Ltd. (Budapest, Hungary). 107 
2.2. Methods 108 
2.2.1. Preparation of spray‐dried products 109 
Optimizing process parameteres, 1% acetic acid chitosan solution was spray‐dried 110 
using Büchi Mini Dryer B‐191 (Switzerland) applying inlet air temperature of 90, 120 111 
and 150 °C and pump rate of 5, 10 and 15 ml/min. Aspirator capacity was 75% (Table 1). 112 
Afterwards, to optimize the composition of the formulation, the feeding emulsions were 113 
prepared of 50 ml 1% chitosan solution, 3.75 ml 4% MEL‐dimethyl sulfoxide (DMSO) 114 
solution and 0, 1 or 2 ml of 1% aqueous solution of TPP applying the optimal parameters 115 
(Table 2). The physical mixtures (PMs) of chitosan, MEL and TPP were produced as the 116 
control samples in the same mass ratio similarly to the spray‐dried products. After 117 
spray‐drying the percentage yield was determined. 118 
Table 1. Spray‐drying process parameters 119 
Inlet air temperature [°C] 90 120 150 
Pump rate [ml/min] 5 10 15 
Table 2. Composition of solutions for spray‐drying 120 
1% chitosan solution [ml] 50 50 50 50 50 50 
1% aqueous TPP solution [ml] ‐ 1 2 ‐ 1 2 
4% MEL-DMSO-solution [ml]  ‐ ‐ ‐ 3.75 3.75 3.75 
2.2.2. Size distribution by Laser diffraction 121 
The particle‐size distribution of the spray‐dried samples was measured by laser 122 
scattering (Malvern Mastersizer Sirocco 2000, Malvern Instruments Ltd, UK). The meas‐ 123 
urements were carried out at 3 bar pressure and 75% frequency, air was used as a dis‐ 124 
persion medium. Approximately 1 g of product was tested in one measurement, and 125 
each measurement was performed 3 times. D0.1, D0.5 and D0.9 values were determined 126 
as the diameter of the particles below which 10, 50 and 90 volume percentage of the par‐ 127 
ticles exist. 128 
2.2.3. Scanning electron microscopy (SEM) 129 
The shape and surface morphology of the spray‐dried particles was visualized by 130 
SEM (Hitachi S4700, Hitachi Scientific Ltd., Tokyo, Japan). Under an argon atmosphere, 131 
the samples were sputter‐coated with gold‐palladium in a high‐vacuum evaporator with 132 
a sputter coater and they were examined at 10 kV and 10 μA. The air pressure was 133 
1.3–13 MPa. 134 
2.2.4. Density measurement 135 
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The bulked and tapped densities of the formulations were measured using the 136 
Engelsmann Stampfvolumeter (Ludwigshafen, Germany) [31]. A 10 cm3 cylinder was 137 
filled with 1.5‐2.0 cm3 powder to calculate bulk density. Then it was tapped 1000 times. 138 
Compared to the volume before and after the taps we calculated the tapped density of 139 
the samples. We calculated the flow characters of the samples from the bulk (ρb) and 140 
tapped (ρt) density (Equation 1): 141 
 (1)
2.2.5. Structural analyses 142 
The thermal analysis was executed with a Mettler Toledo DSC 821e (Germany) 143 
system with the STARe program V9.1 (Mettler Inc., Schwerzenbach, Switzerland). 144 
Approximately 2–5 mg of samples were heated from 25 °C to 300 °C applying 10 145 
°C·min−1 heating rate under a constant argon flow of 10 l·h−1. Physical mixtures of 146 
chitosan, MEL and TPP in the same mass ratio as the spray‐dried samples contained 147 
were mixed in a Turbula mixer (Turbula WAB, Systems Schatz, Switzerland) at 50 rpm 148 
for 10 minutes and were applied as control samples. 149 
XRPD was performed to investigate the physical state of MEL in the samples with a 150 
Bruker D8 Advance diffractometer (Bruker AXS GmbH, Karlsruhe, Germany) with Cu K 151 
λI radiation (λ = 1.5406 Å). The samples were scanned at 40 kV and 40 mA with an 152 
angular range of 3° to 40° 2θ. Si was used to calibrate the instrument. DIFFRACTPLUS 153 
EVA software was used to perform the manipulations: Kα2‐stripping, background 154 
removal and smoothing. 155 
2.2.6. Fourier‐transformed infrared spectroscopy (FT‐IR) 156 
For the purpose of determining whether the cross‐linking and incorporation was 157 
successful, the FT‐IR spectra of the samples was recorded on an AVATAR330 FT‐IR 158 
spectrometer (Thermo Nicolet, Unicam Hungary Ltd., Budapest, Hungary) in the inter‐ 159 
val 400–4000 cm−1, at an optical resolution of 4 cm‐1. Samples were grounded and com‐ 160 
pressed into pastilles at 10 t with 0.15 g of KBr. 161 
2.2.7. Rheological investigations 162 
Rheological measurements were carried out at 32°C with HAAKE RheoStress 1 163 
Rheometer (HAAKE GmbH., Germany). Cone and plate geometry was used to study the 164 
rheological profile of the samples. The flow curve of the samples was determined by ro‐ 165 
tation tests controlled shear rate. The shear rate was increased from 0.1 to 100 1/s in con‐ 166 
trolled rate mode. 167 
2.2.8. In vitro dissolution 168 
The European Pharmacopoeia (6th Edition) paddle method (USP dissolution appa‐ 169 
ratus, type II Pharma Test, Heinburg, Germany) was applied to appoint the dissolution 170 
of MEL. 50 ml of phosphate buffer solution (pH 5.6 ± 0.1) at 30 ± 0.5 °C was used as a 171 
dissolution medium. Taking into account the drug content of the microparticles samples 172 
containing 6 mg of MEL were dispersed. The rotation speed of the paddles was 100 rpm. 173 
At predetermined intervals, the amount of dissolved MEL was determined by spectro‐ 174 
photometry (UNICAM UV/Vis Spectrometer, Germany) at 364 nm. The in vitro drug re‐ 175 
lease data of products were evaluated kinetically using various mathematical models 176 
such as zero order, first order, Higuchi, Hixon–Crowell and Korsmeyer‐Peppas model 177 
[32]. 178 
2.2.9. In vitro permeability 179 
The In vitro permeability of MEL was studied on a modified horizontal diffusion 180 
model which simulated the nasal cavity circumstances (Figure 1). Samples containing 6 181 
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mg of MEL were added to the donor phase (9 ml) which was simulated nasal electrolyte 182 
solution (SNES) of pH 6.0 ± 0.1 (represented the nasal cavity). Half amount of the SNES 183 
was put into the donor chamber and with its other half the sample was washed in the 184 
donor phase. PB of pH 7.40 ‐ which corresponded with the pH of the blood ‐ was used as 185 
the acceptor phase (9 ml). The two chambers were divided by a synthetic membrane 186 
(Whatman® regenerated cellulose membrane filter with 0.45 μm pores) that was soaked 187 
in isopropyl myristate before the investigation. It modelled the lipophilic mucosa be‐ 188 
tween the phases. The temperature of the phases was 30 °C (Thermo Haake C10‐P5, 189 
Sigma, Aldrich Co.) and the rotation rate of the stir‐bars was set to 100 rpm. The amount 190 
of MEL diffused to the acceptor phase was determined spectrophotometrically at 364 nm 191 
in real time with an AvaLight DH‐S‐BAL spectrophotometer (AVANTES, Netherlands). 192 
Each measurement was carried out in triplicate. 193 
 194 
Figure 1. Illustration of in vitro permeability investigation 195 
3. Results 196 
3.1. Particle size distribution 197 
The analysis of the results measured by laser diffraction revealed the fact that by 198 
changing the process parameters, the average particle size of spray‐dried products was 199 
approximately between 2‐4 μm. Since the inlet air temperature and pump rate did not 200 
have any effect on the size distribution of chitosan microspheres (Table 3), we chose the 201 
mild 90 °C inlet air temperature (requiring the least heat energy) and the relatively quick 202 
10 ml/min pump rate to produce the cross‐linked and MEL‐containing particles. At 203 
15 ml/min pump rate there was not sufficient time for the atomized drops to dry, so they 204 
stuck to the column wall. The usage of TPP as a cross‐linking material did not have any 205 
impact on the sizes of drug‐free chitosan particles, however there was a noticeable 206 
increase in the size of MEL‐containing particles, especially when the volume of 207 
TPP‐solution was boosted (Table 4). Based on the literature data, the produced product 208 
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size is considered to be an appropriate one for nasal administration [33]. The yields of 209 
the samples were between 38‐64% concerning the MEL‐free products and they reached 210 
the 29‐48% range regarding the MEL‐containing microspheres. 211 
Table 3. Optimization of the process parameters 212 
Sample 1  2 3 4 5 6 7 8 9 
Inlet air temperature [°C] 90  120 150 90 120 150 90 120 150 
Pump rate [ml/min] 5  5 5 10 10 10 15 15 15 
Aspirator [%] 75  75 75 75 75 75 75 75 75 
D0.1 [μm] 1.044  1.446 1.529 1.176 1.255 1.241 1.115 1.274 1.369 
D0.5 [μm] 2.374  3.669 3.736 2.466 2.815 2.701 2.263 2.629 2.889 
D0.9 [μm] 5.216  8.535 9.032 5.102 5.903 5.519 4.744 5.195 5.664 
Table 4. Optimization of the composition 213 
Sample 4 10 11 12 13 14 
Inlet air temperature [°C]  90 90 90 90 90 90 
Pump rate [ml/min] 10 10 10 10 10 10 
Aspirator [%] 75 75 75 75 75 75 
1% aqueous TPP-solution [ml] ‐ 1 2 ‐ 1 2 
MEL-DMSO-solution [ml]  ‐ ‐ ‐ 3.75 3.75 3.75 
D0.1 [μm] 1.176 1.243 1.103 1.269 1.426 1.617 
D0.5 [μm] 2.466 2.595 2.419 2.965 3.757 5.575 
D0.9 [μm] 5.102 5.234 5.138 7.211 9.461 15.995 
3.2 Morphology of the samples 214 
The SEM images provided an indication of the microspheres morphology. Products 215 
formulated by using different amounts of TPP solution (0, 1.0, 2.0 ml) were investigated. 216 
Drug‐free particles (Sample 4, 10, 11) had a hollow structure. Nearly spherical 217 
microparticles were observed in case of MEL‐containing samples (Sample 12, 13, 14). 218 
Drug‐containing samples in the presence of 0 or 1.0 ml TPP solution revealed a 219 
depressed surface morphology with holes. Microspheres cross‐linked with 2.0 ml TPP 220 
solution exhibited a smooth surface (Figure 2). 221 




Figure 2. SEM images of spray‐dried samples 223 
3.3. Powder rheology properties 224 
The rheological properties of powders have a key role in their processability. 225 
Moreover, the deposition of particles in the nasal cavity is inversely proportional to the 226 
density. Hence, the density of microspheres has a key role in the getting into required 227 
nasal region. The lower density of particles could offer better flowability and an 228 
improved deposition. The bulked and tapped densities, furthermore the Carr‐index 229 
values of formulations are shown in Table 5. In case of drug‐containing products the 230 
tapped density was around 0.15 g/cm3, lower comparing to the drug‐free samples, 231 
predicting drug deposition in the required nasal regions. The Carr‐index results were in 232 
the range of 17 and 29, indicatin the flowability, which parameter is also responsible for 233 
the deposition. 234 
Table 5. Powder rheology properties of the products 235 
Sample  4 10 11 12 13 14 
Bulk 0.2490 0.1384 0.3112 0.1256 0.1176 0.1193 
Density [g/cm3] 
Tap 0.6225 0.2214 0.5187 0.1507 0.1470 0.1670 
Carr-index [%] 60 38 40 17 20 29 
3.4. Structural characterization by DSC and XRPD 236 
DSC was applied to study the crystallinity and the melting of MEL in physical 237 
mixtures and in spray‐dried products. Sharp endothermic peaks of MEL were observed 238 
in the physical mixtures (around 256 °C) that corresponded to the melting point of MEL 239 
indicated that in these cases MEL was crystalline (Figure 3/a). Chitosan is an amorphous 240 
additive. The endothermic peaks of crystalline MEL disappeared; only the characteristic 241 
curve of chitosan was recognized regarding the spray‐dried products containing TPP, 242 
revealing the presence of MEL in a molecularly dispersed form. The non‐cross‐linked 243 
Pharmaceutics 2021, 13, x FOR PEER REVIEW 8 of 14 
 
 
sample (Sample 12) presented a reduced MEL peak intensity referring to the presence of 244 
its crystalline fraction. 245 
XRPD was employed to investigate the physical state of drug‐containing 246 
spray‐dried samples and PMs as controls. The XRPD diffractograms of PMs 247 
demonstrated the crystalline structure of MEL as established during DSC 248 
measurements. Its characteristic peaks were detected at 13.22, 15.06 and 25.7° (2Θ). The 249 
diffractograms of the spray‐dried samples reconfirmed the presence of drug, especially 250 
in the molecularly dispersed form. Few of the peaks of MEL appeared with a reduced 251 
but growing intensity with the decrease of TPP content suggesting the presence of 252 
crystalline MEL (Figure 3/b). The highest amount of crystalline MEL form was found 253 
where no cross‐linking agent was applied. 254 
  
(a) (b) 
Figure 3. (a) DSC curves of PMs (Chit_MEL_2mlTPP‐sol., Chit_MEL_1mlTPP‐sol., Chit_MEL) and MEL‐containing 255 
spray‐dried samples; (b) XRPD patterns of PMs and MEL‐containing spray‐dried samples 256 
3.5 FTIR investigations 257 
The intermolecular interactions of the microspheres were characterized by FTIR 258 
(Figure 4/a). Seven characterization peaks were observed in HMW chitosan–TPP 259 
microspheres at 3363.41, 2881.27, 1646.15 to 1653.24, 1376.47 to 1587.93, 1058.24 to 260 
1064.48, 1026.87 to 1028.81, and 886.58 to 894.85 cm−1. These peaks could be defined as 261 
O–H from H‐bonded, C–H stretch form aldehyde, C=N and N–H from amine I and 262 
amide II, ‐CH3 symmetrical deformation, C–N from amine, C–O stretching, and C–H 263 
from alkene or aromatic bonds, respectively [34,35]. Increasing the amount of TPP the 264 
peaks at 3363.41 cm−1 became broad, indicating an enhancement in hydrogen bonding. 265 
The peak at 1646.15 to 1650.20 cm−1 became larger in the presence of TPP compared to 266 
chitosan alone thanks to the electrostatic interaction between the amino groups in 267 
chitosan and the phosphoric groups in TPP [36]. The TPP peak at 1127.29 cm−1 268 
disappeared after chitosan and TPP cross‐linking due to the intermolecular interactions 269 
of chitosan and TPP. MEL‐containing microparticles showed the characteristic 270 
absorption bands at specific wavenumbers (Figure 4/b) The intensity of characteristic 271 
peaks of MEL at 3290.13, 1550.56 and 1265.14 cm−1 decreased because of drug 272 
incorporation to the microsphere. 273 





Figure 4. (a) FTIR curves of the raw materials and spray dried samples without MEL, (b) FTIR curves of the 274 
PMs and MEL‐containing spray dried samples 275 
3.6. In vitro dissolution study 276 
Before the dissolution studies, microspheres were dispersed in phosphate buffer 277 
(pH = 5.6) and the viscosity of samples was detected. Samples displayed shear‐thinning 278 
behaviour, thanks to the orientation of the polimer chains in the flow direction. The 279 
viscosity of samples increased with increasing the TPP amount.  280 
The in vitro dissolution test was carried out at pH of 5.6 in phosphate buffer 281 
simulating the nasal conditions. The dissolution of raw MEL and of MEL from 282 
cross‐linked and non‐cross‐linked samples was studied. Unprocessed MEL was used as 283 
a control, only 4.5% of it dissolved in 60 min (Table 6). The spray‐dried samples 284 
revealed fast initial release in the first 15 minutes, which was followed by a slower stage. 285 
The presence of drug in a molecularly dispersed form resulted in the rapid dissolution 286 
of API from the microspheres. The dissolved amount of MEL was decreased by the 287 
growth of TPP concentration. The lowest dissolved amount of drug was perceptible in 288 
the presence of 2 ml TPP. The highest amount of MEL – more than 90% during 1 h – has 289 
been dissolved from the non‐cross‐linked Sample 12. This phenomena could be 290 
explained with the formation of cross‐links only as the result of reaction between the 291 
phosphate and the amino groups of chitosan in case of Sample 12 [37]. Adding TPP, the 292 
enhancement in hydrogen bonding and the electrostatic interaction between the amino 293 
and the phosphoric groups of chitosan and TPP kept MEL inside the microparticles. 294 
During the analyses of the kinetics of drug release the data was evaluated by 295 
correlation coefficient (R2). R2 values were used as the criteria to choose the best model to 296 
describe drug release from the products (Table 7). Because of the low solubility, the 297 
dissolution of raw MEL was slow and fitted the zero order kinetics model. In case of 298 
TPP‐free spray‐dried product (Sample 12), the strongest correlation was shown with the 299 
first order kinetics model (Equation 2): 300 
 
(2)
where Mt is the cumulative amount of drug released at time “t”; M∞ is the initial 301 
amount of drug in the dosage form; k is the release rate constant, revealing that the 302 
dissolution rate was concentration dependent. Approaching the saturation 303 
concentration, the dissolution slowed down. Concerning Sample 13 and 14 the drug 304 
release fitted the Korsmeyer‐Peppas model (Equation 3): 305 
 
(3)




(where n is a constant, which characterizes the transport mechanism of diffusion), 307 
indicating that the drug release mechanism from these samples was diffusion controlled 308 
by gelling and the slow erosion of the chitosan [38]. 309 
Table 6 The percentage of dissolved drug from raw MEL and MEL‐containing 310 
spray‐dried products 311 
Time (min.) Dissolved drug (%) 
 raw MEL Sample 12 Sample 13 Sample 14 
5 0.157 ± 0.01 50.15 ± 2.44 35.53 ± 2.51 48.85 ± 1.78 
10 0.583 ± 0.03 60.24 ± 3.05 47.62 ± 3.01 60.96 ± 2.38 
15 1.003 ± 0.05 68.18 ± 3.76 55.97 ± 3.41 75.20 ± 2.80 
30 2.618 ± 0.13 78.37 ± 3.10 67.53 ± 3.92 79.93 ± 3.38 
60 4.548 ± 0.23 82.38 ± 4.68 73.28 ± 4.1 93.65 ± 3.66 
Table 7 R2 values of kinetic analysis of in vitro drug release using different models 312 
raw MEL Sample 12 Sample 13 Sample 14 
Model 
R2 R2 R2 R2 
Zero order 0.9927 0.7658 0.7309 0.7787 
First‐order 0.989 0.9685 0.8626 0.8732 
Higuchi 0.8021 0.7799 0.6757 0.8234 
Hixon–Crowell 0.9892 0.8304 0.6634 0.7354 
Korsmeyer‐Peppas 0.9756 0.945 0.9528 0.9496 
3.7. In vitro diffusion study 313 
Modified diffusion horizontal cell model was used for diffusion investigations. 314 
Figure 5 demonstrates that the rapid dissolution of MEL from molecularly dispersed 315 
state in case of the spray‐dried products resulted in a faster diffusion and a higher 316 
permeated drug concentration in the acceptor phase. The lowest drug amount 317 
permeated related to raw MEL. The highest diffused concentration was observed from 318 
the product which did not contain TPP in its composition (approximately 45 ug/cm2). In 319 
the presence of TPP chitosan formed a well‐structured complex due to the 320 
intermolecular interactions, resulting decreased swelling capacity of the polymer matrix 321 
and less drug dissolution and diffusion. 322 




Figure 5. In vitro permeability of raw MEL and of MEL‐containing spray‐dried products 324 
4. Conclusions 325 
The aim of our work was to prepare MEL‐containing spray‐dried chitosan micro‐ 326 
spheres for nasal administration. The effect of the process parameters (inlet air tem‐ 327 
perature and pump rate) on the particle size and morphology of the microspheres was 328 
studied. As a novelty, a lower inlet air temperature (90 °C) was investigated than 329 
usaually. With the chosen parameters cross‐linked and MEL‐containing samples were 330 
formulated. The physicochemical (particles size, shape, crystalline‐ and chemical struc‐ 331 
ture) and rheological properties of the microspheres were characterized, and the disso‐ 332 
lution rate and diffusion through the artificial membrane of the drug‐containing pow‐ 333 
ders were investigated. 334 
The inlet air temperature and pump rate did not have an effect on the particle size 335 
distribution and morphology, therefore the parameters that required the least energy (90 336 
°C) and resulted in fast drying (10 ml/min) were chosen. Hereinafter, applying these pa‐ 337 
rameters, MEL‐containing samples were prepared adding different amounts of TPP so‐ 338 
lutions (0, 1 or 2 ml). The size of spray‐dried MEL containing microparticles increased 339 
compared to the drug‐free particles, however, the average particle size was between 340 
2.9‐5.6 μm, and they had a spherical habit. The density of microspheres (around 0.15 341 
g/cm3) predicted drug deposition in the respiratory region of nose. In the spray‐dried 342 
samples, MEL was primarily in a molecularly dispersed state, however, concerning the 343 
non‐cross‐linked samples a small crystalline fraction of MEL was observed. The MEL 344 
incorporation to the chitosan microparticles was successful. According to the in vitro 345 
dissolution and permeability studies, the amount of dissolved and diffused MEL was 346 
decreased by raising the concentration of TPP. In case of microspheres that were formu‐ 347 
lated without TPP more than 90% of drug was dissolved during 1 h, and the same 348 
product showed highest permeated drug amount (≈45 ug/cm2). It can be explained by the 349 
formed cross‐links so that chitosan retained MEL from dissolution and diffusion. For all 350 
three samples, the initial rapid dissolution was followed by a decelerating drug release. 351 
Because of the mucoadhesive and permeability‐enhancer features of chitosan and 352 
the fast and continuous dissolution and diffusion of molecularly dispersed MEL, for‐ 353 
mulated microspheres prepared by spray‐drying may be recommended for further op‐ 354 
timization in order to develop nasal dosage form. After the dose settings and the choice 355 
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and setting of medical device which is suitable for nasal powder delivery, the drug de‐ 356 
livery system may be suggested for relieving acute pain or as adjuvant of analgesia 357 
through the nasal mucosa. 358 
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